Indications and uses
Triamcinolone acetonide cream 0.025% and 0.1% are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Triamcinolone acetonide cream 0.025% and 0.1% are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Apply the 0.1% triamcinolone acetonide cream to the affected area two to three times daily. Rub in gently. Occlusive Dressing Technique Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Gently rub a small amount of cream into the lesion until it disappears. Reapply the preparation leaving a thin coating on the lesion, cover with a pliable nonporous film, and seal the...
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid freezing. CAUTION: FEDERAL LAW PROHIBITS DISPENSING WITHOUT PRESCRIPTION.
The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. The steroids in this class include triamcinolone acetonide. Triamcinolone acetonide is designated chemically as 9-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone. Graphic formula:
Each gram of 0.1% triamcinolone acetonide cream provides 1 mg of triamcinolone acetonide, respectively, in a cream base containing cetyl alcohol, isopropyl palmitate, methyl paraben, mineral oil/lanolin alcohol, polysorbate 40, propyl paraben, propylene glycol, propylene glycol monostearate, purified water, sorbic acid, sorbitan monopalmitate, stearyl alcohol and xanthan gum.
Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions.
The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.
Pharmacokinetics
The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.
Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (see DOSAGE AND ADMINISTRATION).
Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Triamcinolone acetonide cream 0.025% and 0.1% are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.
General
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.
Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.
Therefore, patients receiving a large dose of any potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests, and for impairment of thermal homeostasis. If HPA axis suppression or elevation of the body temperature occurs, an attempt should be made to withdraw the drug, to reduce the frequency of application, substitute a less potent steroid, or use a sequential approach when utilizing the occlusive technique.
Recovery of HPA axis function and thermal homeostasis are generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Occasionally, a patient may develop a sensitivity reaction to a particular occlusive dressing material or adhesive and a substitute material may be necessary.
Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see PRECAUTIONS, Pediatric Use).
If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.
In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.
These preparations are not for ophthalmic use.
Patients using topical corticosteroids should receive the following information and instructions:
1. This medication is to be used as directed by the physician. It is for dermatologic use only. Avoid contact with the eyes.
2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.
4. Patients should report any signs of local adverse reactions especially under occlusive dressing.
5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.
A urinary free cortisol test and ACTH stimulation test may be helpful in evaluating HPA axis suppression.
Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.
Studies to determine mutagenicity with prednisolone and hydrocortisone showed negative results.
Teratogenic Effects
Category C.
Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.
Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.
HPA axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.
Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.
The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS, General)
Apply the 0.1% triamcinolone acetonide cream to the affected area two to three times daily. Rub in gently.
Occlusive Dressing Technique
Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Gently rub a small amount of cream into the lesion until it disappears. Reapply the preparation leaving a thin coating on the lesion, cover with a pliable nonporous film, and seal the edges. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication. The frequency of changing dressings is best determined on an individual basis. It may be convenient to apply triamcinolone acetonide cream under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion). When utilizing the 12-hour occlusion regimen, additional cream should be applied, without occlusion, during the day. Reapplication is essential at each dressing change.
If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Triamcinolone Acetonide Cream, USP 0.1% is supplied in tubes containing 80 g (NDC 0603-7862-90).
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid freezing.
CAUTION: FEDERAL LAW PROHIBITS DISPENSING WITHOUT PRESCRIPTION.
Dimethicone 5%
Skin protectant
For external use only
Edetate Disodium, Isoproply Palmitate, Methylparaben, Paraffin, Petrolatum, Propylene Glycol, Potassium Chloride, Propylparaben, Sodium Chloride, Water, Beeswax
Uses
Precautions
Directions for use
NDC: 75840-093-01 Rx Only
SanaDermRx Skin Repair Solution
NDC: 0603-7862-90
Triamcinolone Acetonide Cream USP 0.1% (80 g)
NDC: 50484-322-00
Skin Repair Complex-Dimethicone 5.0% (114g)
Silicone Medical Tape- (1 roll)
Package Size-1 Kit (each)
EthiPak, LLC
Store at 20°-25°C (68°-77°F)
(See USP Control Room Temperature)
Warning: Keep this and all medications out of reach of Children
For Dermatologic Use Only. Not Ophthalmic
Directions for use:
(See Enclosed Package Insert)
Manufactured By: GenPak Solutions, LLC
For EthuPak, LLC
4324 Reynolds Drive
Hilliard, Ohio 43026
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 259090 | dimethicone 5 % Topical Cream | PSN | 2 |
| 1014314 | triamcinolone acetonide 0.1 % Topical Cream | PSN | 2 |
| 259090 | dimethicone 50 MG/ML Topical Cream | SCD | 2 |
| 1014314 | triamcinolone acetonide 1 MG/ML Topical Cream | SCD | 2 |
| 259090 | dimethicone 5 % Topical Cream | SY | 2 |
| 1014314 | triamcinolone acetonide 0.1 % Topical Cream | SY | 2 |
| 1014314 | triamcinolone acetonide 1 MG per GM Topical Cream | SY | 2 |
| Class | Version | Type | Effective |
|---|---|---|---|
| DIMETHICONE Pharmacologic Class Indexing | 3 | Indexing - Pharmacologic Class | 20180813 |
| TRIAMCINOLONE ACETONIDE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 75840-093-01 | 2020-01-31 | C162847 | 48780-1 | 9d75b9cf-f6dd-f424-e053-dadaa90a57ce | SanaDermRx Skin Repair Solution |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0603-7862-90 | SanaDermRx SKin Repair | 80 g in 1 TUBE | CREAM | 80 g | 1 mg in 1g | 2 |
| 50484-322-00 | SanaDermRx SKin Repair | 114 g in 1 TUBE | CREAM | 114 g | 50 mg in 1g | 2 |
| 75840-093-01 | SanaDermRx SKin Repair | 1 in 1 CARTON | KIT | 1 | 2 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 0603-7862 | SANADERMRX SKIN REPAIR (TRIAMCINOLONE ACETONIDE CREAM KIT) KIT [GENPAK SOLUTIONS, LLC] | 2 | Legacy NDC | 20151019_17e3afd1-3526-4324-a756-1a426dfe7875.zip |
| 50484-322 | SANADERMRX SKIN REPAIR (TRIAMCINOLONE ACETONIDE CREAM KIT) KIT [GENPAK SOLUTIONS, LLC] | 2 | Unmatched | 20151019_17e3afd1-3526-4324-a756-1a426dfe7875.zip |
| 75840-093 | SANADERMRX SKIN REPAIR (TRIAMCINOLONE ACETONIDE CREAM KIT) KIT [GENPAK SOLUTIONS, LLC] | 2 | Legacy NDC, 3 package rows | 20151019_17e3afd1-3526-4324-a756-1a426dfe7875.zip |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 75840-093-01 | EA - Each | 75840-093 | 05d6a65a-9ddc-47c1-90d4-a72ccda06524 | 1 | 2015-12-02 |
| 0603-7862-74 | GM - Gram | 0603-7862 | 7ada8ac8-ec04-4031-9751-fb8f5a790b38 | 1 | 2012-07-24 |
| 0603-7862-78 | GM - Gram | 0603-7862 | d9f77d2a-4385-4315-9a7f-9439e73af888 | 1 | 2014-06-03 |
| 0603-7862-90 | GM - Gram | 0603-7862 | ac7849d3-8ea7-4135-b4cf-8f5d2581ca59 | 1 | 2012-07-24 |
| 50484-322-00 | GM - Gram | 50484-322 | df6595e7-3678-415a-9f6a-a1036d98eddd | 1 | 2013-03-03 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| DIMETHICONE | ACTIVE INGREDIENT | 92RU3N3Y1O | 2 | |
| TRIAMCINOLONE ACETONIDE | ACTIVE INGREDIENT | F446C597KA | 2 | |
| DIMETHICONE | ACTIVE MOIETY | 92RU3N3Y1O | 2 | |
| TRIAMCINOLONE ACETONIDE | ACTIVE MOIETY | F446C597KA | 2 | |
| EDETATE DISODIUM | INACTIVE INGREDIENT | 7FLD91C86K | 2 | |
| ISOPROPYL PALMITATE | INACTIVE INGREDIENT | 8CRQ2TH63M | 2 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 2 | |
| PARAFFIN | INACTIVE INGREDIENT | I9O0E3H2ZE | 2 | |
| PETROLATUM | INACTIVE INGREDIENT | 4T6H12BN9U | 2 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 2 | |
| PROPYLPARABEN | INACTIVE INGREDIENT | Z8IX2SC1OH | 2 | |
| SODIUM CHLORIDE | INACTIVE INGREDIENT | 451W47IQ8X | 2 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 2 | |
| YELLOW WAX | INACTIVE INGREDIENT | 2ZA36H0S2V | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 75840-093 | 75840-093-01 |
| 0603-7862 | 0603-7862-90 |
| 50484-322 | 50484-322-00 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| TRIAMCINOLONE ACETONIDE | F446C597KA | ACTIB |
| DIMETHICONE | 92RU3N3Y1O | ACTIB |
| EDETATE DISODIUM | 7FLD91C86K | IACT |
| ISOPROPYL PALMITATE | 8CRQ2TH63M | IACT |
| METHYLPARABEN | A2I8C7HI9T | IACT |
| PARAFFIN | I9O0E3H2ZE | IACT |
| PETROLATUM | 4T6H12BN9U | IACT |
| PROPYLENE GLYCOL | 6DC9Q167V3 | IACT |
| PROPYLPARABEN | Z8IX2SC1OH | IACT |
| SODIUM CHLORIDE | 451W47IQ8X | IACT |
| WATER | 059QF0KO0R | IACT |
| YELLOW WAX | 2ZA36H0S2V | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / ORAL | 22602 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION/ DROPS / TOPICAL | 0.23 %w/v | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | SOAP / TOPICAL | 0.85 %w/w | ||
| PARAFFIN | PARAFFIN | I9O0E3H2ZE | OINTMENT / TOPICAL | 2860 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.16 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION, CONCENTRATE / ORAL | 2590 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | CAPSULE / ORAL | 5 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, COATED / ORAL | 54.7 mg | ||
| YELLOW WAX | YELLOW WAX | 2ZA36H0S2V | TABLET, COATED / ORAL | 213.7 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION/ DROPS / AURICULAR (OTIC) | ADJ PH | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | OINTMENT / OPHTHALMIC | 88.4 %w/w | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SPRAY / RESPIRATORY (INHALATION) | 0.05 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRAVASCULAR | 0.86 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TAMPON / VAGINAL | 62.1 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / INTRALESIONAL | 0.02 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION / ORAL | 64 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, CHEWABLE / ORAL | 20 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / INTRAVENOUS | 90 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SOLUTION / RESPIRATORY (INHALATION) | 43 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | EMULSION / TOPICAL | 0.06 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | POWDER / ORAL | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, SOLUTION / SUBCUTANEOUS | 1.4 %w/v | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | ELIXIR / ORAL | 1.3 mg/5ml | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | LIQUID / ORAL | 2 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | CREAM / VAGINAL | 22 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | GEL / OPHTHALMIC | 0.9 %w/v | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | TABLET / ORAL | 3.5 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / NASAL | 140 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRABURSAL | 9 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 6 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, METERED / RECTAL | NA | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | CREAM, AUGMENTED / TOPICAL | 26 %w/w | ||
| YELLOW WAX | YELLOW WAX | 2ZA36H0S2V | CAPSULE / ORAL | 44 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SPONGE / TOPICAL | 40 %w/w | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / PARENTERAL | 210 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY, METERED / NASAL | 240 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 0.4 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / RESPIRATORY (INHALATION) | 108 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION/ DROPS / OPHTHALMIC | 3 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | LIQUID / NASAL | 2 mg/1ml | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / NASAL | 7.4 mg/1ml | ||
| PARAFFIN | PARAFFIN | I9O0E3H2ZE | OINTMENT / RECTAL | 38 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / ORAL | 27120 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SYRUP / ORAL | 40 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | JELLY / TOPICAL | 420 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / RECTAL | 1808 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION, SUSPENSION / INTRAMUSCULAR | 1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / INTRACAUDAL | 210 mg | ||
| PARAFFIN | PARAFFIN | I9O0E3H2ZE | TABLET, DELAYED RELEASE / ORAL | 0.2 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / INTRAMUSCULAR | 0.13 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / SUBCUTANEOUS | 0.8 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION / SUBCUTANEOUS | 1.4 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | OINTMENT / TOPICAL | 29 mg | ||
| PARAFFIN | PARAFFIN | I9O0E3H2ZE | CAPSULE, EXTENDED RELEASE / ORAL | 100 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION / INTRAVENOUS | 10 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SPRAY / TOPICAL | 0.8 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / SOFT TISSUE | 0.02 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / INTRAMUSCULAR | 26 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / RETROBULBAR | 648 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / SUBCUTANEOUS | 0.7 %w/v |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A040671-001 | TRIAMCINOLONE ACETONIDE | TRIAMCINOLONE ACETONIDE | 0.025% | CREAM / TOPICAL | AT | 2006-06-09 | |
| A040671-002 | TRIAMCINOLONE ACETONIDE | TRIAMCINOLONE ACETONIDE | 0.1% | CREAM / TOPICAL | AT | 2006-06-09 |
| Application-product | TE code |
|---|---|
| A040671-001 | AT |
| A040671-002 | AT |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A040671-001 | TRIAMCINOLONE ACETONIDE | 0.025% | CREAM / TOPICAL | AT | 2006-06-09 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A040671-002 | TRIAMCINOLONE ACETONIDE | 0.1% | CREAM / TOPICAL | AT | 2006-06-09 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | A040671-001 | TRIAMCINOLONE ACETONIDE | 0.025% | CREAM / TOPICAL | AT | 2006-06-09 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A040671-002 | TRIAMCINOLONE ACETONIDE | 0.1% | CREAM / TOPICAL | AT | 2006-06-09 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A040671-001 | TRIAMCINOLONE ACETONIDE | 0.025% | CREAM / TOPICAL | AT | 2006-06-09 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A040671-002 | TRIAMCINOLONE ACETONIDE | 0.1% | CREAM / TOPICAL | AT | 2006-06-09 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A040671-001 | TRIAMCINOLONE ACETONIDE | 0.025% | CREAM / TOPICAL | AT | 2006-06-09 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A040671-002 | TRIAMCINOLONE ACETONIDE | 0.1% | CREAM / TOPICAL | AT | 2006-06-09 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A040671-001 | TRIAMCINOLONE ACETONIDE | 0.025% | CREAM / TOPICAL | AT | 2006-06-09 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A040671-002 | TRIAMCINOLONE ACETONIDE | 0.1% | CREAM / TOPICAL | AT | 2006-06-09 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A040671-001 | TRIAMCINOLONE ACETONIDE | 0.025% | CREAM / TOPICAL | AT | 2006-06-09 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A040671-002 | TRIAMCINOLONE ACETONIDE | 0.1% | CREAM / TOPICAL | AT | 2006-06-09 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A040671-001 | TRIAMCINOLONE ACETONIDE | 0.025% | CREAM / TOPICAL | AT | 2006-06-09 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | A040671-002 | TRIAMCINOLONE ACETONIDE | 0.1% | CREAM / TOPICAL | AT | 2006-06-09 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A040671-001 | TRIAMCINOLONE ACETONIDE | 0.025% | CREAM / TOPICAL | AT | 2006-06-09 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A040671-002 | TRIAMCINOLONE ACETONIDE | 0.1% | CREAM / TOPICAL | AT | 2006-06-09 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A040671-001 | TRIAMCINOLONE ACETONIDE | 0.025% | CREAM / TOPICAL | AT | 2006-06-09 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A040671-002 | TRIAMCINOLONE ACETONIDE | 0.1% | CREAM / TOPICAL | AT | 2006-06-09 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A040671-001 | TRIAMCINOLONE ACETONIDE | 0.025% | CREAM / TOPICAL | AT | 2006-06-09 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A040671-002 | TRIAMCINOLONE ACETONIDE | 0.1% | CREAM / TOPICAL | AT | 2006-06-09 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A040671-001 | TRIAMCINOLONE ACETONIDE | 0.025% | CREAM / TOPICAL | AT | 2006-06-09 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A040671-002 | TRIAMCINOLONE ACETONIDE | 0.1% | CREAM / TOPICAL | AT | 2006-06-09 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A040671-001 | TRIAMCINOLONE ACETONIDE | 0.025% | CREAM / TOPICAL | AT | 2006-06-09 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A040671-002 | TRIAMCINOLONE ACETONIDE | 0.1% | CREAM / TOPICAL | AT | 2006-06-09 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A040671-001 | TRIAMCINOLONE ACETONIDE | 0.025% | CREAM / TOPICAL | AT | 2006-06-09 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A040671-002 | TRIAMCINOLONE ACETONIDE | 0.1% | CREAM / TOPICAL | AT | 2006-06-09 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | A040671-001 | TRIAMCINOLONE ACETONIDE | 0.025% | CREAM / TOPICAL | AT | 2006-06-09 | d06236e962d9… | |
| 2024-10-29 15:01 UTC | 2024-10 | A040671-002 | TRIAMCINOLONE ACETONIDE | 0.1% | CREAM / TOPICAL | AT | 2006-06-09 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A040671-001 | TRIAMCINOLONE ACETONIDE | 0.025% | CREAM / TOPICAL | AT | 2006-06-09 | 79d66fd596c7… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A040671-002 | TRIAMCINOLONE ACETONIDE | 0.1% | CREAM / TOPICAL | AT | 2006-06-09 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A040671-001 | TRIAMCINOLONE ACETONIDE | 0.025% | CREAM / TOPICAL | AT | 2006-06-09 | 301d65b070ca… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A040671-002 | TRIAMCINOLONE ACETONIDE | 0.1% | CREAM / TOPICAL | AT | 2006-06-09 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A040671-001 | TRIAMCINOLONE ACETONIDE | 0.025% | CREAM / TOPICAL | AT | 2006-06-09 | 1e350fbaab3a… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A040671-002 | TRIAMCINOLONE ACETONIDE | 0.1% | CREAM / TOPICAL | AT | 2006-06-09 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | A040671-001 | TRIAMCINOLONE ACETONIDE | 0.025% | CREAM / TOPICAL | AT | 2006-06-09 | 8072bd15b7f6… | |
| 2024-05-31 18:47 UTC | 2024-05 | A040671-002 | TRIAMCINOLONE ACETONIDE | 0.1% | CREAM / TOPICAL | AT | 2006-06-09 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A040671-001 | TRIAMCINOLONE ACETONIDE | 0.025% | CREAM / TOPICAL | AT | 2006-06-09 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A040671-002 | TRIAMCINOLONE ACETONIDE | 0.1% | CREAM / TOPICAL | AT | 2006-06-09 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A040671-001 | TRIAMCINOLONE ACETONIDE | 0.025% | CREAM / TOPICAL | AT | 2006-06-09 | 5d02ea3f76ae… | |
| 2022-04-08 23:34 UTC | 2022-04 | A040671-002 | TRIAMCINOLONE ACETONIDE | 0.1% | CREAM / TOPICAL | AT | 2006-06-09 | 5d02ea3f76ae… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A040671-001 | AT | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A040671-002 | AT | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A040671-001 | AT | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A040671-002 | AT | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A040671-001 | AT | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A040671-002 | AT | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A040671-001 | AT | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A040671-002 | AT | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A040671-001 | AT | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A040671-002 | AT | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A040671-001 | AT | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A040671-002 | AT | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A040671-001 | AT | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A040671-002 | AT | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A040671-001 | AT | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A040671-002 | AT | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A040671-001 | AT | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A040671-002 | AT | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A040671-001 | AT | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A040671-002 | AT | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A040671-001 | AT | 1 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A040671-002 | AT | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A040671-001 | AT | 1 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A040671-002 | AT | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A040671-001 | AT | 1 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A040671-002 | AT | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A040671-001 | AT | 1 | d06236e962d9… |
| 2024-10-29 15:01 UTC | 2024-10 | A040671-002 | AT | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A040671-001 | AT | 1 | 79d66fd596c7… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A040671-002 | AT | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A040671-001 | AT | 1 | 301d65b070ca… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A040671-002 | AT | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A040671-001 | AT | 1 | 1e350fbaab3a… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A040671-002 | AT | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A040671-001 | AT | 1 | 8072bd15b7f6… |
| 2024-05-31 18:47 UTC | 2024-05 | A040671-002 | AT | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A040671-001 | AT | 1 | 5c6f7cd8ea54… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A040671-002 | AT | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A040671-001 | AT | 1 | 5d02ea3f76ae… |
| 2022-04-08 23:34 UTC | 2022-04 | A040671-002 | AT | 1 | 5d02ea3f76ae… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 9dd6b162-d299-4403-a262-f5554162f046 | 17e3afd1-3526-4324-a756-1a426dfe7875 | 2015-10-19 | Warnings, Adverse reactions | 9dd6b162-d299-4403-a262-f5554162f046 17e3afd1-3526-4324-a756-1a426dfe7875 |
Adverse event summaries are temporarily unavailable. Other product information remains available.